Royce & Associates’s Larimar Therapeutics LRMR Stock Holding History

Royce & Associates’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-28,064	Closed	-$90K	–	937
2022 Q3	$90K	Hold	28,064	–	–	﹤0.01%	904
2022 Q2	$55K	Hold	28,064	–	–	﹤0.01%	930
2022 Q1	$114K	Hold	28,064	–	–	﹤0.01%	946
2021 Q4	$303K	Hold	28,064	–	–	﹤0.01%	931
2021 Q3	$324K	Hold	28,064	–	–	﹤0.01%	946
2021 Q2	$276K	Hold	28,064	–	–	﹤0.01%	970
2021 Q1	$410K	Hold	28,064	–	–	﹤0.01%	963
2020 Q4	$601K	Hold	28,064	–	–	0.01%	866
2020 Q3	$426K	Hold	28,064	–	–	﹤0.01%	873
2020 Q2	$361K	Sell	28,064 -1	-0%	-$12	﹤0.01%	888
2020 Q1	$259K	Hold	28,065	–	–	﹤0.01%	891
2019 Q4	$374K	Hold	28,065	–	–	﹤0.01%	919
2019 Q3	$249K	Hold	28,065	–	–	﹤0.01%	970
2019 Q2	$401K	Hold	28,065	–	–	﹤0.01%	933
2019 Q1	$923K	Hold	28,065	–	–	0.01%	866
2018 Q4	$1.67M	Sell	28,065 -9,050	-24%	-$893K	0.01%	779
2018 Q3	$5.21M	Sell	37,115 -1,667	-4%	-$202K	0.04%	587
2018 Q2	$4.76M	Hold	38,782	–	–	0.03%	603
2018 Q1	$3.47M	Sell	38,782 -6,926	-15%	-$587K	0.02%	680
2017 Q4	$2.53M	Buy	45,708 +18,000	+65%	+$811K	0.02%	790
2017 Q3	$1.17M	Hold	27,708	–	–	0.01%	923
2017 Q2	$1.17M	Sell	27,708 -4,083	-13%	-$209K	0.01%	936
2017 Q1	$1.78M	Sell	31,791 -10,215	-24%	-$507K	0.01%	888
2016 Q4	$1.6M	Hold	42,006	–	–	0.01%	868
2016 Q3	$1.67M	Buy	+42,006	New	+$1.91M	0.01%	849

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Royce & Associates's LRMR Position: Q4 2022 in Review

Royce & Associates sold out of Larimar Therapeutics (LRMR) in Q4 2022, closing a stake of 28,064 shares — an estimated $90K sold.

Royce & Associates first reported a position in LRMR in Q3 2016 and held it in 25 quarters. The position peaked at $5.21M in Q3 2018. 48 funds tracked by Wall St. Rank hold LRMR as of Q4 2022.

Royce & Associates reported no remaining Larimar Therapeutics position as of Q4 2022 after selling out during the quarter.
Royce & Associates sold 28,064 Larimar Therapeutics shares in Q4 2022, an estimated $90K.
Royce & Associates first reported a position in Larimar Therapeutics in Q3 2016 and held it in 25 quarters.
Royce & Associates's Larimar Therapeutics position peaked at $5.21M in Q3 2018.
48 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2022.

Based on Royce & Associates's 13F filing for Q4 2022, filed 13 Feb 2023.